Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab/Tuvonralimab plus chemotherapy for NSCLC leptomeningeal metastasis
ChiCTR2500108332Phase 4Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of iparomlimab + tuvonralimab in non-small cell lung cancer (NSCLC) and Carcinomatous Meningitis (CM), sponsored by Huashan Hospital. Primary endpoint: overall survival. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
non-small cell lung cancer (NSCLC)Carcinomatous Meningitis (CM)
Beyond the preview
Go deeper on ChiCTR2500108332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108332.